This exchange stock is a buy on renewed options deal, Morgan Stanley says

Morgan Stanley double-upgraded Cboe Global Markets to overweight from underweight and raised its price target to $358 from $258, implying nearly 22% upside from Thursday's close, after Cboe renewed its S&P DJI options agreement through 2051. The bank raised its EPS estimates for the next two years to 16% and 18%, citing stronger volumes, improved capture and lower expenses; prediction-market products could add upside not included in those estimates. The bullish call contrasts with broader analyst sentiment: 7 of 19 analysts rate the stock a buy and 11 a hold; shares are up 17% year to date.

Analysis

The durable asset is not simply the renewed license; it is Cboe’s ability to monetize concentrated demand for benchmark index risk through trading activity and execution economics. That can support resilience when single-stock options cool, but the benefit depends on volume and capture rates—not contract duration alone. Institutional users can substitute toward futures or other hedges, limiting pricing power; monitor whether SPX options activity outperforms broader options volumes.

The prediction-market thesis is higher-variance than the core franchise. KPI contracts could create a new data and transaction-fee pool, but commercial scale, customer demand, regulatory treatment, and any effect on existing products remain unproven. Treat it as optionality, not base-case earnings, until Cboe reports measurable participation and monetization. The long-dated agreement reduces a major franchise uncertainty, but undisclosed economics leave room for less upside than the headline implies.

Near term, a crowded upgrade narrative after a strong year-to-date move raises pullback risk. Over 1–3 months, earnings commentary on options volumes, capture, and costs matters more than the analyst target. Over 6–18 months, sustained index-options growth and evidence that new contracts attract incremental users would validate a higher-quality growth profile. The contrarian risk is that investors capitalize an unproven product while overlooking the possibility that volumes normalize. Thesis weakens if SPX activity or capture underperforms the broader options market, expense leverage disappoints, or regulators constrain KPI contracts.

Key Decisions for Investors

• Favor a staged long in CBOE rather than chasing strength: add on weakness or after results confirm sustained options activity and capture. The core thesis is franchise durability; do not underwrite prediction markets in the base case.
• Keep the KPI-contract launch on an alert list, not as a standalone catalyst trade. Before assigning value, verify regulatory status, launch timing, participation, and disclosed revenue or volume contribution.
• Track CBOE’s SPX options volume and capture against broader options activity, plus expense trends. Persistent relative underperformance or weaker operating leverage would falsify the earnings-quality thesis and warrant reducing exposure.
• Avoid treating the extended agreement as proof of unconstrained pricing power. Watch for substitution into futures and other hedges; evidence of share or capture loss would challenge the assumed moat.